Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.
Identifieur interne : 000041 ( Main/Exploration ); précédent : 000040; suivant : 000042Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.
Auteurs : Paul A. Yates [États-Unis] ; Steven A. Newman [États-Unis] ; Lauren J. Oshry [États-Unis] ; Robert H. Glassman [États-Unis] ; Ashton M. Leone [États-Unis] ; Elias Reichel [États-Unis]Source :
- Therapeutic advances in respiratory disease [ 1753-4666 ]
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Adénocarcinome pulmonaire (complications), Adénocarcinome pulmonaire (diagnostic), Adénocarcinome pulmonaire (thérapie), Appréciation des risques (MeSH), Broncho-pneumopathie chronique obstructive (complications), Broncho-pneumopathie chronique obstructive (diagnostic), Broncho-pneumopathie chronique obstructive (thérapie), Comorbidité (MeSH), Doxycycline (administration et posologie), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (complications), Infections à coronavirus (diagnostic), Infections à coronavirus (traitement médicamenteux), Multimorbidité (MeSH), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (diagnostic), Pneumopathie virale (traitement médicamenteux), Résultat thérapeutique (MeSH), Sarcoïdose pulmonaire (complications), Sarcoïdose pulmonaire (diagnostic), Sarcoïdose pulmonaire (thérapie), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Études de suivi (MeSH), Études par échantillonnage (MeSH).
- MESH :
- administration et posologie : Doxycycline.
- diagnostic : Adénocarcinome pulmonaire, Broncho-pneumopathie chronique obstructive, Infections à coronavirus, Pneumopathie virale, Sarcoïdose pulmonaire.
- thérapie : Adénocarcinome pulmonaire, Broncho-pneumopathie chronique obstructive, Sarcoïdose pulmonaire.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- complications : Adulte, Adulte d'âge moyen, Adénocarcinome pulmonaire, Appréciation des risques, Broncho-pneumopathie chronique obstructive, Comorbidité, Femelle, Humains, Infections à coronavirus, Multimorbidité, Mâle, Pandémies, Pneumopathie virale, Résultat thérapeutique, Sarcoïdose pulmonaire, Sujet âgé, Sujet âgé de 80 ans ou plus, Études de suivi, Études par échantillonnage.
English descriptors
- KwdEn :
- Adenocarcinoma of Lung (complications), Adenocarcinoma of Lung (diagnosis), Adenocarcinoma of Lung (therapy), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Comorbidity (MeSH), Coronavirus Infections (complications), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Doxycycline (administration & dosage), Female (MeSH), Follow-Up Studies (MeSH), Humans (MeSH), Male (MeSH), Middle Aged (MeSH), Multimorbidity (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), Pulmonary Disease, Chronic Obstructive (complications), Pulmonary Disease, Chronic Obstructive (diagnosis), Pulmonary Disease, Chronic Obstructive (therapy), Risk Assessment (MeSH), Sampling Studies (MeSH), Sarcoidosis, Pulmonary (complications), Sarcoidosis, Pulmonary (diagnosis), Sarcoidosis, Pulmonary (therapy), Treatment Outcome (MeSH).
- MESH :
- chemical , administration & dosage : Doxycycline.
- complications : Adenocarcinoma of Lung, Coronavirus Infections, Pneumonia, Viral, Pulmonary Disease, Chronic Obstructive, Sarcoidosis, Pulmonary.
- diagnosis : Adenocarcinoma of Lung, Coronavirus Infections, Pneumonia, Viral, Pulmonary Disease, Chronic Obstructive, Sarcoidosis, Pulmonary.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- therapy : Adenocarcinoma of Lung, Pulmonary Disease, Chronic Obstructive, Sarcoidosis, Pulmonary.
- Adult, Aged, Aged, 80 and over, Comorbidity, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multimorbidity, Pandemics, Risk Assessment, Sampling Studies, Treatment Outcome.
Abstract
Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive.Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposing of safer, established medications that may have antiviral activity is a possible approach for treatment of earlier-stage disease. Tetracycline and its derivatives (e.g. doxycycline and minocycline) are nontraditional antibiotics with a well-established safety profile, potential efficacy against viral pathogens such as dengue fever and chikungunya, and may regulate pathways important in initial infection, replication, and systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19+ patients, with known pulmonary disease, treated with doxycycline with subsequent rapid clinical improvement. No safety issues were noted with use of doxycycline.Doxycycline is an attractive candidate as a repurposed drug in the treatment of COVID-19 infection, with an established safety profile, strong preclinical rationale, and compelling initial clinical experience described here.The reviews of this paper are available via the supplemental material section.
DOI: 10.1177/1753466620951053
PubMed: 32873175
PubMed Central: PMC7476338
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.</title><author><name sortKey="Yates, Paul A" sort="Yates, Paul A" uniqKey="Yates P" first="Paul A" last="Yates">Paul A. Yates</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author><author><name sortKey="Newman, Steven A" sort="Newman, Steven A" uniqKey="Newman S" first="Steven A" last="Newman">Steven A. Newman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author><author><name sortKey="Oshry, Lauren J" sort="Oshry, Lauren J" uniqKey="Oshry L" first="Lauren J" last="Oshry">Lauren J. Oshry</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Boston University School of Medicine, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Boston University School of Medicine, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Glassman, Robert H" sort="Glassman, Robert H" uniqKey="Glassman R" first="Robert H" last="Glassman">Robert H. Glassman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Weill Cornell Medicine, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Leone, Ashton M" sort="Leone, Ashton M" uniqKey="Leone A" first="Ashton M" last="Leone">Ashton M. Leone</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author><author><name sortKey="Reichel, Elias" sort="Reichel, Elias" uniqKey="Reichel E" first="Elias" last="Reichel">Elias Reichel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 Jan-Dec</date><idno type="RBID">pubmed:32873175</idno><idno type="pmid">32873175</idno><idno type="doi">10.1177/1753466620951053</idno><idno type="pmc">PMC7476338</idno><idno type="wicri:Area/Main/Corpus">000399</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000399</idno><idno type="wicri:Area/Main/Curation">000399</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000399</idno><idno type="wicri:Area/Main/Exploration">000399</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.</title><author><name sortKey="Yates, Paul A" sort="Yates, Paul A" uniqKey="Yates P" first="Paul A" last="Yates">Paul A. Yates</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author><author><name sortKey="Newman, Steven A" sort="Newman, Steven A" uniqKey="Newman S" first="Steven A" last="Newman">Steven A. Newman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author><author><name sortKey="Oshry, Lauren J" sort="Oshry, Lauren J" uniqKey="Oshry L" first="Lauren J" last="Oshry">Lauren J. Oshry</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Boston University School of Medicine, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Boston University School of Medicine, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Glassman, Robert H" sort="Glassman, Robert H" uniqKey="Glassman R" first="Robert H" last="Glassman">Robert H. Glassman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Weill Cornell Medicine, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Leone, Ashton M" sort="Leone, Ashton M" uniqKey="Leone A" first="Ashton M" last="Leone">Ashton M. Leone</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author><author><name sortKey="Reichel, Elias" sort="Reichel, Elias" uniqKey="Reichel E" first="Elias" last="Reichel">Elias Reichel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><series><title level="j">Therapeutic advances in respiratory disease</title><idno type="eISSN">1753-4666</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma of Lung (complications)</term><term>Adenocarcinoma of Lung (diagnosis)</term><term>Adenocarcinoma of Lung (therapy)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Comorbidity (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (drug therapy)</term><term>Doxycycline (administration & dosage)</term><term>Female (MeSH)</term><term>Follow-Up Studies (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Multimorbidity (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pulmonary Disease, Chronic Obstructive (complications)</term><term>Pulmonary Disease, Chronic Obstructive (diagnosis)</term><term>Pulmonary Disease, Chronic Obstructive (therapy)</term><term>Risk Assessment (MeSH)</term><term>Sampling Studies (MeSH)</term><term>Sarcoidosis, Pulmonary (complications)</term><term>Sarcoidosis, Pulmonary (diagnosis)</term><term>Sarcoidosis, Pulmonary (therapy)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Adénocarcinome pulmonaire (complications)</term><term>Adénocarcinome pulmonaire (diagnostic)</term><term>Adénocarcinome pulmonaire (thérapie)</term><term>Appréciation des risques (MeSH)</term><term>Broncho-pneumopathie chronique obstructive (complications)</term><term>Broncho-pneumopathie chronique obstructive (diagnostic)</term><term>Broncho-pneumopathie chronique obstructive (thérapie)</term><term>Comorbidité (MeSH)</term><term>Doxycycline (administration et posologie)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (diagnostic)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Multimorbidité (MeSH)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (diagnostic)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Résultat thérapeutique (MeSH)</term><term>Sarcoïdose pulmonaire (complications)</term><term>Sarcoïdose pulmonaire (diagnostic)</term><term>Sarcoïdose pulmonaire (thérapie)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Études de suivi (MeSH)</term><term>Études par échantillonnage (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Doxycycline</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Doxycycline</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Adenocarcinoma of Lung</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Pulmonary Disease, Chronic Obstructive</term><term>Sarcoidosis, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Adenocarcinoma of Lung</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Pulmonary Disease, Chronic Obstructive</term><term>Sarcoidosis, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Adénocarcinome pulmonaire</term><term>Broncho-pneumopathie chronique obstructive</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Sarcoïdose pulmonaire</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Adenocarcinoma of Lung</term><term>Pulmonary Disease, Chronic Obstructive</term><term>Sarcoidosis, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Adénocarcinome pulmonaire</term><term>Broncho-pneumopathie chronique obstructive</term><term>Sarcoïdose pulmonaire</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Comorbidity</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Multimorbidity</term><term>Pandemics</term><term>Risk Assessment</term><term>Sampling Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Adénocarcinome pulmonaire</term><term>Appréciation des risques</term><term>Broncho-pneumopathie chronique obstructive</term><term>Comorbidité</term><term>Femelle</term><term>Humains</term><term>Infections à coronavirus</term><term>Multimorbidité</term><term>Mâle</term><term>Pandémies</term><term>Pneumopathie virale</term><term>Résultat thérapeutique</term><term>Sarcoïdose pulmonaire</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études de suivi</term><term>Études par échantillonnage</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive.Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposing of safer, established medications that may have antiviral activity is a possible approach for treatment of earlier-stage disease. Tetracycline and its derivatives (e.g. doxycycline and minocycline) are nontraditional antibiotics with a well-established safety profile, potential efficacy against viral pathogens such as dengue fever and chikungunya, and may regulate pathways important in initial infection, replication, and systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19<sup>+</sup> patients, with known pulmonary disease, treated with doxycycline with subsequent rapid clinical improvement. No safety issues were noted with use of doxycycline.Doxycycline is an attractive candidate as a repurposed drug in the treatment of COVID-19 infection, with an established safety profile, strong preclinical rationale, and compelling initial clinical experience described here.<i>The reviews of this paper are available via the supplemental material section.</i></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32873175</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1753-4666</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><MedlineDate>2020 Jan-Dec</MedlineDate></PubDate></JournalIssue><Title>Therapeutic advances in respiratory disease</Title><ISOAbbreviation>Ther Adv Respir Dis</ISOAbbreviation></Journal><ArticleTitle>Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.</ArticleTitle><Pagination><MedlinePgn>1753466620951053</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1753466620951053</ELocationID><Abstract><AbstractText>Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive.Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposing of safer, established medications that may have antiviral activity is a possible approach for treatment of earlier-stage disease. Tetracycline and its derivatives (e.g. doxycycline and minocycline) are nontraditional antibiotics with a well-established safety profile, potential efficacy against viral pathogens such as dengue fever and chikungunya, and may regulate pathways important in initial infection, replication, and systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19<sup>+</sup> patients, with known pulmonary disease, treated with doxycycline with subsequent rapid clinical improvement. No safety issues were noted with use of doxycycline.Doxycycline is an attractive candidate as a repurposed drug in the treatment of COVID-19 infection, with an established safety profile, strong preclinical rationale, and compelling initial clinical experience described here.<i>The reviews of this paper are available via the supplemental material section.</i></AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yates</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oshry</LastName><ForeName>Lauren J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glassman</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leone</LastName><ForeName>Ashton M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichel</LastName><ForeName>Elias</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9523-9046</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Respir Dis</MedlineTA><NlmUniqueID>101316317</NlmUniqueID><ISSNLinking>1753-4658</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>N12000U13O</RegistryNumber><NameOfSubstance UI="D004318">Doxycycline</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000077192" MajorTopicYN="N">Adenocarcinoma of Lung</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004318" MajorTopicYN="N">Doxycycline</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076322" MajorTopicYN="N">Multimorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029424" MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012494" MajorTopicYN="N">Sampling Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017565" MajorTopicYN="N">Sarcoidosis, Pulmonary</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">doxycycline</Keyword><Keyword MajorTopicYN="Y">pulmonary disease</Keyword><Keyword MajorTopicYN="Y">therapeutic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32873175</ArticleId><ArticleId IdType="doi">10.1177/1753466620951053</ArticleId><ArticleId IdType="pmc">PMC7476338</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell Mol Immunol. 2020 Apr 7;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32265513</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharm Sin B. 2020 May;10(5):766-788</Citation><ArticleIdList><ArticleId IdType="pubmed">32292689</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48</Citation><ArticleIdList><ArticleId IdType="pubmed">20592239</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2020 Sep;158(3):892-895</Citation><ArticleIdList><ArticleId IdType="pubmed">32360495</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging (Albany NY). 2020 Mar 30;12(8):6511-6517</Citation><ArticleIdList><ArticleId IdType="pubmed">32229706</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010 Nov 04;6(11):e1001176</Citation><ArticleIdList><ArticleId IdType="pubmed">21079686</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Res. 2010 May 1;86(2):211-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20202975</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Oct;82(20):9880-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18701591</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2015 Jul 30;7(8):4230-53</Citation><ArticleIdList><ArticleId IdType="pubmed">26264019</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2017 Mar 29;91(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">28148786</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotox Res. 2016 May;29(4):447-59</Citation><ArticleIdList><ArticleId IdType="pubmed">26745968</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2017 May 16;135(20):1935-1950</Citation><ArticleIdList><ArticleId IdType="pubmed">28179397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Microbiol Antimicrob. 2020 May 15;19(1):18</Citation><ArticleIdList><ArticleId IdType="pubmed">32414383</ArticleId></ArticleIdList></Reference><Reference><Citation>IDCases. 2020 Jun 06;21:e00864</Citation><ArticleIdList><ArticleId IdType="pubmed">32566483</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermatol Ther. 2020 Apr 20;:e13437</Citation><ArticleIdList><ArticleId IdType="pubmed">32314492</ArticleId></ArticleIdList></Reference><Reference><Citation>J Periodontol. 2008 Mar;79(3):469-76</Citation><ArticleIdList><ArticleId IdType="pubmed">18315429</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 May 13;10(5):e0126360</Citation><ArticleIdList><ArticleId IdType="pubmed">25970853</ArticleId></ArticleIdList></Reference><Reference><Citation>Recent Pat Antiinfect Drug Discov. 2015;10(1):51-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25858261</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Respir J. 2020 May 7;55(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">32269088</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li><li>Virginie</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Virginie"><name sortKey="Yates, Paul A" sort="Yates, Paul A" uniqKey="Yates P" first="Paul A" last="Yates">Paul A. Yates</name></region><name sortKey="Glassman, Robert H" sort="Glassman, Robert H" uniqKey="Glassman R" first="Robert H" last="Glassman">Robert H. Glassman</name><name sortKey="Leone, Ashton M" sort="Leone, Ashton M" uniqKey="Leone A" first="Ashton M" last="Leone">Ashton M. Leone</name><name sortKey="Newman, Steven A" sort="Newman, Steven A" uniqKey="Newman S" first="Steven A" last="Newman">Steven A. Newman</name><name sortKey="Oshry, Lauren J" sort="Oshry, Lauren J" uniqKey="Oshry L" first="Lauren J" last="Oshry">Lauren J. Oshry</name><name sortKey="Reichel, Elias" sort="Reichel, Elias" uniqKey="Reichel E" first="Elias" last="Reichel">Elias Reichel</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000041 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000041 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32873175
|texte= Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32873175" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |